PE20151766A1 - Agentes quelantes de precursores de producto final de glicacion avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Info

Publication number
PE20151766A1
PE20151766A1 PE2015001994A PE2015001994A PE20151766A1 PE 20151766 A1 PE20151766 A1 PE 20151766A1 PE 2015001994 A PE2015001994 A PE 2015001994A PE 2015001994 A PE2015001994 A PE 2015001994A PE 20151766 A1 PE20151766 A1 PE 20151766A1
Authority
PE
Peru
Prior art keywords
age
precursors
end product
chelating agents
advanced glycation
Prior art date
Application number
PE2015001994A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20151766A1 publication Critical patent/PE20151766A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
PE2015001994A 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age) PE20151766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151766A1 true PE20151766A1 (es) 2015-12-11

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001994A PE20151766A1 (es) 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG11201506413PA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112020003638A2 (pt) * 2017-08-31 2020-09-01 Cytosorbents Corporation redução de produtos finais de glicação avançada a partir de fluidos corporais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
ES2637020T3 (es) * 2001-04-18 2017-10-10 Genzyme Corporation Uso de polímero de amina para reducir la glucosa sérica
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
JP2007523908A (ja) * 2004-02-17 2007-08-23 ダイナミス セラピューティクス インコーポレイテッド フルクトサミン3キナーゼ並びにコラーゲン及びエラスチンの形成
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US9181364B2 (en) * 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
CR20150545A (es) 2015-12-01
SG11201506413PA (en) 2015-09-29
EP2968403A1 (en) 2016-01-20
JP2018135365A (ja) 2018-08-30
PH12015502019A1 (en) 2016-01-11
BR112015023404A2 (pt) 2017-07-18
BR112015023404A8 (pt) 2019-12-03
CA2906501A1 (en) 2014-09-25
MX2015012843A (es) 2016-08-08
AU2014235500A1 (en) 2015-11-05
US20160024233A1 (en) 2016-01-28
EA201591733A1 (ru) 2016-01-29
HK1220607A1 (zh) 2017-05-12
KR20150130492A (ko) 2015-11-23
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
CL2015002624A1 (es) 2016-03-11
US20180265613A1 (en) 2018-09-20
MA38487A1 (fr) 2017-12-29
DOP2015000221A (es) 2015-12-15
JP2022037143A (ja) 2022-03-08
JP2020055850A (ja) 2020-04-09
AR095593A1 (es) 2015-10-28
JP2016512830A (ja) 2016-05-09
IL241406A0 (en) 2015-11-30
WO2014150873A1 (en) 2014-09-25
UY35441A (es) 2014-10-31
AU2019201259A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2018014758A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
CL2016001150A1 (es) Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.
MX386598B (es) Compuestos antibacterianos.
MX380092B (es) Tratamiento de la osteoartritis.
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
EA201400754A2 (ru) Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их
TN2016000022A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12017502201A1 (en) Substituted pyridines and method of use
PH12015502075A1 (en) Treatment of cataplexy
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
EA201390381A1 (ru) Триазиноксадиазолы
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MY178251A (en) New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
MX382175B (es) Composiciones de profármaco de monometilfumarato
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
PE20151766A1 (es) Agentes quelantes de precursores de producto final de glicacion avanzada (age)
EA201491581A1 (ru) Везикулярные композиции
EA201591449A1 (ru) Способы получения противораковых композиций
EA201501177A1 (ru) Фармацевтические композиции